rDEN2delta30-7169

Phase 1

NNational Institute of Allergy and Infectious Diseases (NIAID)

rDEN2delta30-7169 is one of 5 therapeutic programs targeting Dengue. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

DengueRecruiting

DenguePhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Dengue

#DrugCompanyPhaseTrials

Lagevrio

Merck & Co.

Phase 2

1 2

Rden2δ30-7169

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 3

Biological

NNational Environment Agency, Singapore

Preclinical

2 4

rDEN2delta30-7169

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 5

Emetine Hydrochloride

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Dengue

NCT07706686

Clinical

Trials by Indication[1]

Dengue1 trial

Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07706686·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for rDEN2delta30-7169. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for rDEN2delta30-7169. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

rDEN2delta30-7169

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Dengue1 trial

References

Drug Info

Quick Facts

Related News